Analysts Set Korro Bio, Inc. (NASDAQ:KRRO) PT at $142.17

Shares of Korro Bio, Inc. (NASDAQ:KRRO) have been given an average recommendation of “Buy” by the six analysts that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $142.17.

Several equities analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $115.00 price objective on shares of Korro Bio in a research note on Wednesday, November 13th. Raymond James assumed coverage on shares of Korro Bio in a research note on Monday, October 21st. They issued a “strong-buy” rating and a $153.00 price objective on the stock. William Blair reissued an “outperform” rating on shares of Korro Bio in a research note on Wednesday, November 13th. Finally, Royal Bank of Canada boosted their target price on shares of Korro Bio from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Monday, October 21st.

Insider Buying and Selling at Korro Bio

In related news, CFO Vineet Agarwal sold 10,216 shares of the stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $78.26, for a total transaction of $799,504.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 5.40% of the stock is owned by insiders.

Institutional Trading of Korro Bio

Several large investors have recently bought and sold shares of KRRO. Bank of New York Mellon Corp acquired a new stake in Korro Bio in the second quarter valued at approximately $649,000. Rhumbline Advisers purchased a new position in shares of Korro Bio during the 2nd quarter valued at approximately $279,000. Atlas Venture Life Science Advisors LLC boosted its stake in shares of Korro Bio by 1.6% during the 2nd quarter. Atlas Venture Life Science Advisors LLC now owns 1,137,149 shares of the company’s stock valued at $38,515,000 after buying an additional 17,857 shares during the last quarter. Brown Brothers Harriman & Co. bought a new position in Korro Bio during the second quarter worth $28,000. Finally, Tri Locum Partners LP bought a new position in Korro Bio during the second quarter worth $2,419,000. Institutional investors and hedge funds own 13.18% of the company’s stock.

Korro Bio Stock Down 4.3 %

Shares of Korro Bio stock opened at $47.56 on Friday. The firm’s fifty day simple moving average is $50.05 and its 200-day simple moving average is $46.68. Korro Bio has a 12 month low of $30.00 and a 12 month high of $98.00.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($2.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.55) by $0.29. Equities analysts predict that Korro Bio will post -9.63 EPS for the current year.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).